OMG - hadn't seen this thread! Out-phackin-standing!! Great laughs on a Monday morning.
Can't wait til this board is shut down.
Covered another 1/3 at $29.71-$29.72.
While it reached my target, I have decided to leave a third on. Not only is it house money, but recent events have convinced me that it's not done yet - so I will take advantage of what I think will be further tankage.
Best of luck to everyone.
Maybe because there's still doubt in many minds - after being told there would be no buybacks until the fiori deal closed, now they're being told they've been buying in the open market, management is buying, etc.....
Credibility is a precious commodity. NQ doesn't have any. With good reason.
I'm not covering. :)
Probably a lot of short covering by those who wanted to shift their (massive) gains into 2015 (like me, lol). Can't help but pop a little with that much buying going on. Temporary, imo.
The rest I'm leaving there just for entertainment. Just how low will she go before delisting? If so many deluded longs hadn't lost so much money, it would actually be funny - but I take no pleasure in other peoples' losses. At some point you have to see what's staring you all right in front of you. Hopefully most of you will see the light soon.
Best of luck.
LOL, only took a couple of hours for the mental case to start posting again. Now he can't stop - using all of his aliases. Not to mention already deleting some of today's posts.
2) $5 million over 5 years, 05/01/2013 to 04/30/2018, at a fixed price of (iirc) $579/bottle. Might be off on the price, but it was for whatever the current price was on 4/24/13 (when the contract was awarded).
Perhaps attach a Breathalyzer that the user has to blow into, to prove they aren't already hammered before using the unit. Sadly, they don't make an idiot detector yet. :)
ALISO VIEJO, Calif., Nov. 7, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has issued preliminary written feedback to its New Drug Application (NDA) for AVP-825. AVP-825 is a drug-device combination product consisting of low-dose sumatriptan powder, delivered intranasally utilizing a novel Breath Powered delivery technology. The FDA has raised questions regarding the human factor validation study data submitted as part of the NDA. Human factor testing focuses on the interactions between people and devices. The goal of human factor testing is to evaluate use-related risks and confirm that users can use the device safely and effectively. Although the NDA review is ongoing, Avanir has concluded, at this time, that approval of AVP-825 may be unlikely by the PDUFA date of November, 26, 2014.
The FDA feedback was provided via a Discipline Review letter, which is a standard vehicle to convey early thoughts on possible deficiencies of an application. In the letter, the FDA requested that the company optimize the product-user interface and conduct additional human factor testing. In addition, the FDA commented that the NDA review is not complete and that they may have additional comments regarding the application.
"We are currently reviewing the correspondence from the FDA and are awaiting the final feedback when the full NDA review cycle is complete on November 26th," said Joao Siffert, MD, chief medical officer of Avanir. "We plan to work closely with the FDA to answer the agency's questions and satisfy their requirements. We remain confident that AVP-825 will be an important new treatment option for migraine patients who are in need of alternative, fast acting and well tolerated medications."
Yes, everyone. There's room for us all, and I want everyone to be successful. I take no pleasure in anyone's pain, unlike so many on these boards. To each his own, but this works for me. :)
Thank you. Thank you very much. :)
This report is a disaster, much worse than even I expected. Guidance is horrible. Look out below, folks.
Good luck everyone.